LIMN · Liminatus Pharma, Inc.
$5.16
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.93M
Shares
1.34M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Baek | director | Appointed | 2025-07-11 |
| Philip Lemons | director | Appointed | 2025-07-11 |
| Byong C. Yoo | Chief Science Officer | Appointed | 2025-05-06 |
| Sang-jin Daniel Lee | Head of Research and Development | Appointed | 2025-05-06 |
| Beom K. Choi | Chief Technology Officer | Appointed | 2025-05-06 |
| Chris Kim | Chief Executive Officer | Appointed | 2025-05-06 |
| Omkar Halady | Vice President | Resigned | 2025-05-06 |
| Lisha Parmar | Chief Financial Officer | Resigned | 2025-05-06 |
| Scott Dam | Chief Financial Officer | Appointed | 2025-05-06 |
| Ji Yeon Baek | Director | Appointed | 2025-05-06 |
| Sumit Mehta | Chief Executive Officer | Resigned | 2025-05-06 |
| Eun Sook Lee | Director | Appointed | 2025-05-06 |
| Nicholas Fernandez | Director | Appointed | 2025-05-06 |
| Nicholas Fernandez | board member | Resigned | 2025-05-06 |
| Richard Peretz | board member | Resigned | 2025-05-06 |
| Chris Kim | Director | Appointed | 2025-05-06 |
| Manish Shah | board member | Resigned | 2025-05-06 |
| Rohit Nanani | board member | Resigned | 2025-05-06 |